. Author manuscript; available in PMC: 2016 Aug 1.

Published in final edited form as: Clin Transl Sci. 2014 Nov 12;8(4):394–402. doi: 10.1111/cts.12242

TABLE 2.

Altered Expression of Micro RNAs Reported in BE and/or EAC

STAGE	MICRO RNA*	EXPRESSION	TARGET	CITATIONS
NSM to BE	hsa-miR-136*	Increased	AEG-1 and Bcl-2	^34,37,54
BE to LGD	miR-21	Increased	PTEN, FASL, TIMP3 and RECK, activating ERK1/2/MAPK pathway	^{26,31,34,37,43,55–57}
BE to LGD	miR-31	Increased	EMP1 (epithelial membrane protein 1), KSR2 (kinase suppressor of ras 2) and RGS4 (regulator of G-protein signalling 4) – found in Esophageal Squamous Cell carcinoma	^36,56,58
BE to EAC	miR-25	Increased	Bcl-2-like protein 11^† - apoptosis	^34,59,60
	miR-93	Increased	CDKN1A – cell cycle	^26,60
	miR-106b-25	Increased	CDKN1A – cell cycle	^{34,36,47,60–62}
	hsa-miR-136*	Decreased	^‡	^34,37
	hsa-miR-192	Increased	DHFR, CDC7, LMNB2, MAD2L1, CUL5 – cell cycle, cell proliferation	^{31,34,36,37,56,60,62}
	hsa-miR-194*	Increased	EP300 - metastasis	^{31,36,37,56,60}
	miR-196a/b	Increased	ANXA1, SPRR2C, S1009 and KRT5 - apoptosis	^{24,32,36,60–62}
	hsa-miR-203	Decreased	ABL1, TP63 – cell proliferation	^{11,26,34,36,37,43,56,60,62,63}
	hsa-miR-205	Decreased	HER3, PRKCD, VEGF-A – cell proliferation, EMT	^{11,26,29,34,36,37,43,56,60,62,63}
	hsa-miR-223	Increased	ARTN, a known tumor metastasis-related gene	^{34,36,37,61,64}
	hsa-miR-424*	Increased	^‡	^{9,11,29,34,36,37}
	hsa-miR-450a	Increased	^‡	^34,37
LGD to HGD	miR-15b	Increased	Bcl-2	³⁶
	miR-20b	Decreased	^‡	^34,36,62
	miR-23b	Decreased	c-Myc	^34,36,65
	hsa-miR-101	Increased	rap1GAP – tumor suppressor gene	^36,37,65,66
	miR-125b	Increased	CYP24, ERBB2, ERBB3 – cell proliferation	^{11,34,36,43,60}
	miR-181a/b	Decreased	TIMP- 3^†	^32,36,55,67
	miR-197	Increased	^‡	³⁶
	miR-200a*	Decreased	E-cadherin transcriptional repressors ZEB1 and ZEB2	^{36,55–57,68}
	miR-215	Increased	ZEB2	^{26,34,56,62,68}
	miR-513	Increased	^‡	³⁶
	miR-636	Decreased	^‡	³⁶
HGD to EAC	miR-27b	Decreased	ST14, CYP1B1 - Cell proliferation, cell migration, invasion, drug metabolism	^{36,43,55,59,60,65}
	miR-28	Increased	^‡	³⁶
	miR-30a-5p	Increased	^‡	^34,36
	miR-99a	Decreased	mTOR	^{11,29,34,36,59,62,69}
	miR-126	Increased	EGFL7^†	^36,57,59,70
	miR-143	Increased	FSCN1	^{26,34,36,55,56,59,62}
	miR-145	Increased	FSCN1	^{26,34,36,37,56,57,59}
	miR-149	Decreased	FOXM1^† - EMT	^36,71
	miR-181a/b	Increased	TIMP- 3^†	^32,36,55
	miR-193a/b	Decreased	^‡	³⁶
	miR-199a	Increased	Brm	^36,61,72
	miR-210	Decreased	MNT^† – myc antagonist, FGFRL1	^{24,34,36,65,73}
	miR-345	Decreased	^‡	³⁶
	miR-494	Decreased	^‡	³⁶
	miR-513	Decreased	^‡	³⁶
	miR-617	Decreased	^‡	³⁶
	let-7a/b/c	Decreased	IL-6, Ras, HMGA2	^{32,34,36,57,60,62,63,65}
EAC	miR-16-2	Increased	RAR-b2^†	^36,57
	miR-30e	Increased	^‡	^55,57
	miR-34a	Decreased	NF-κ B Inhibition of c-Met and cyclin D1 protein expression	^36,55,57
	miR-195p	Increased	^‡	^36,55,57
	miR-221	Increased	p27Kip1 and CDX2	^31,33
	miR-222	Increased	p27Kip1 and CDX2	^31,33
	miR-375	Decreased	PDK1, JAK2	^{29,31,33,34,36,37,44,55,56,61,65}
	hsa-miR-518b	Decreased	^‡	^36,37,55

^†

potential target

^‡

unknown target,

Abbreviations: BE = Barrett’s esophagus, EAC = Esophageal Adenocarcinoma, HGD = High Grade Dysplasia, LGD = Low Grade Dysplasia, NSM = Normal Squamous Mucosa